LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Home・Akciju saraksts・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Slēgts

3.41 3.02

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.41

Max

3.41

Galvenie mērījumi
By Trading Economics
Ienākumi	5.5M -28M
Pārdošana	8.2M 13M
Peļņas marža	-208.694
Darbinieki	172
EBITDA	8.7M -27M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+348.25% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 10. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-66M 188M
Iepriekšējā atvēršanas cena	0.39
Iepriekšējā slēgšanas cena	3.41

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

3.17 / 3.4644 Atbalsts un pretestība

Voyager Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 20. febr. 17:37 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Regulatory Waiting Period for Warner Bid Expires -- Update

2026. g. 20. febr. 16:18 UTC

Galvenie tirgus virzītāji

Footwear Stocks Rise After Supreme Court Strikes Down Tariffs

2026. g. 20. febr. 23:12 UTC

Iegādes, apvienošanās, pārņemšana

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

2026. g. 20. febr. 22:12 UTC

Peļņas

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

2026. g. 20. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 20. febr. 21:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 20. febr. 21:23 UTC

Peļņas

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

2026. g. 20. febr. 21:20 UTC

Tirgus saruna

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

2026. g. 20. febr. 21:01 UTC

Iegādes, apvienošanās, pārņemšana

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

2026. g. 20. febr. 20:38 UTC

Tirgus saruna

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

2026. g. 20. febr. 20:17 UTC

Tirgus saruna

Oil Futures Mixed As Market Awaits U.S.-Iran Moves -- Market Talk

2026. g. 20. febr. 20:11 UTC

Tirgus saruna

Traders Await Word on USMCA Exemption For Trump's Global 10% Tariff -- Market Talk

2026. g. 20. febr. 19:59 UTC

Tirgus saruna

U.S. Tariff Ruling Could Make Things Worse for Mexico -- Market Talk

2026. g. 20. febr. 19:58 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Netflix Seen as Not Needing Warner Bros. Deal -- Market Talk

2026. g. 20. febr. 19:49 UTC

Tirgus saruna

Mexico's Revised 4Q GDP Expected to Confirm Pick-Up -- Market Talk

2026. g. 20. febr. 19:09 UTC

Tirgus saruna

Precious Metals Settle Higher After Tariff Ruling -- Market Talk

2026. g. 20. febr. 19:00 UTC

Tirgus saruna

U.S. Oil, Gas Rig Counts Unchanged on Week -- Market Talk

2026. g. 20. febr. 18:28 UTC

Tirgus saruna

Ontario Premier Warns Fight Against U.S. Tariffs Isn't Over -- Market Talk

2026. g. 20. febr. 18:20 UTC

Tirgus saruna

Tariff Ruling Seen Positive for Some Retailers, Mixed for Others -- Market Talk

2026. g. 20. febr. 18:05 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2026. g. 20. febr. 18:04 UTC

Tirgus saruna

Trade Uncertainty in Canada to Remain Until USMCA Resolved -- Market Talk

2026. g. 20. febr. 17:38 UTC

Tirgus saruna

Canada's Small Firms Look Toward Increased U.S. Tariff Opposition -- Market Talk

2026. g. 20. febr. 17:24 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 20. febr. 17:24 UTC

Tirgus saruna

Correction to Treasury Yields Fall Market Talk

2026. g. 20. febr. 17:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 20. febr. 16:53 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2026. g. 20. febr. 16:53 UTC

Tirgus saruna

Canada Dollar Steady, Market Focus on USMCA Review -- Market Talk

2026. g. 20. febr. 16:45 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 20. febr. 16:45 UTC

Tirgus saruna

U.K. Public Finances Supportive of Gilts in Near-Term -- Market Talk

2026. g. 20. febr. 16:40 UTC

Tirgus saruna

Trade Threats Facing Canada Not Removed by Supreme Court's Ruling -- Market Talk

Salīdzinājums

Cenas izmaiņa

Voyager Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

348.25% augšup

Prognoze 12 mēnešiem

Vidējais 15.33 USD 348.25%

Augstākais 25 USD

Zemākais 10 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

3 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 3 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

3.17 / 3.4644Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.